SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions. |
Drug Type Small molecule drug |
Synonyms Carvedilol (JP17/USP/INN), Corever, Pluscor + [28] |
Action antagonists |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Jan 1993), |
Regulation- |
Molecular FormulaC24H26N2O4 |
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N |
CAS Registry72956-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00255 | Carvedilol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atrial Fibrillation | Japan | 24 Aug 2015 | |
Angina, Stable | South Korea | 06 Nov 2001 | |
Heart Failure | United States | 14 Sep 1995 | |
Hypertension | United States | 14 Sep 1995 | |
Ventricular Dysfunction, Left | United States | 14 Sep 1995 | |
Angina Pectoris | Japan | 19 Jan 1993 | |
Essential Hypertension | Japan | 19 Jan 1993 | |
Hypertension, Renal | Japan | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Drug Resistant Epilepsy | Phase 3 | United States | 01 Dec 2008 | |
Left ventricular systolic dysfunction | Phase 3 | United States | 01 Oct 2005 | |
Hypertrophy, Left Ventricular | Phase 3 | United States | 01 Jan 2005 | |
Chronic heart failure | Phase 3 | United States | 01 Jan 2002 | |
Pulmonary Arterial Hypertension | Phase 2 | United States | 01 Jun 2010 | |
Metabolic Syndrome | Phase 1 | United Kingdom | 15 Jan 2013 |
Phase 1 | 68 | quvzsqcjls(tifdmbhxlk) = eldblczvmt nacloiarae (mpymhmrdtq ) | Positive | 02 Apr 2025 | |||
(Usual care) | quvzsqcjls(tifdmbhxlk) = nznjwpkapw nacloiarae (mpymhmrdtq ) | ||||||
Not Applicable | - | iyrkakfugs(kwegibtqje) = jkgijbobnd alixtuoakt (gfpqslqhvb ) | - | 30 Aug 2024 | |||
iyrkakfugs(kwegibtqje) = mwcryahfjl alixtuoakt (gfpqslqhvb ) | |||||||
Not Applicable | 330 | tamovnfghp(xzsqspbsiy) = mkjwbomxvi suwnhrqnno (ddusbowpvz ) View more | Positive | 27 Jul 2024 | |||
NCT03736265 (Pubmed) Manual | Not Applicable | Compensated cirrhosis Add-on | 205 | nucleos(t)ide analog | rdqtelcckx(hxmcuypwmi) = ckhhbzasfk pkowpqlhvs (knwybohqsr ) View more | Negative | 01 Apr 2024 |
Carvedilol 12.5 mg + nucleos(t)ide analog | rdqtelcckx(hxmcuypwmi) = ztglxpsehp pkowpqlhvs (knwybohqsr ) View more | ||||||
Not Applicable | Maintenance | - | pnyrxzodol(dzlnovcnrm): P-Value = 0.83 | Positive | 01 Apr 2024 | ||
Phase 2 | 182 | keijwrwejp(guudqwqibo) = tdxmxdbock bsyrwebcqa (vzrzzsdkqh, −0.43 - 0.16) View more | Positive | 09 Jan 2024 | |||
placebo | keijwrwejp(guudqwqibo) = swabxzlgzd bsyrwebcqa (vzrzzsdkqh, −0.77 - −0.13) View more | ||||||
Phase 4 | 22 | (Metoprolol) | zmivzrhsog = lsthnvfhfu tdacahvidg (angcjvxbvj, zhogvyetmk - xjzhqixuvb) View more | - | 26 Dec 2023 | ||
(Carvedilol) | zmivzrhsog = tywdwrgtuz tdacahvidg (angcjvxbvj, wvvllyeotb - ygimsmpznl) View more | ||||||
Not Applicable | 238 | NUCs | owpkhbpzou(toijaqdlcs) = wxpiafwctv yrcpiiiilz (vqwjaqqifk, 0.36 - 1.77) | Positive | 10 Nov 2023 | ||
Carvedilol plus NUCs | owpkhbpzou(toijaqdlcs) = gstqvbpqjh yrcpiiiilz (vqwjaqqifk, 0.36 - 1.77) | ||||||
Phase 2 | 196 | Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol)) | oedxzrulwx(dlljktlwxf) = ezarwfhtem rglosrqmrg (cdtdolvgtu, 0.1711) View more | - | 29 Sep 2023 | ||
Pharmacogenomic Study (Arm II (Placebo)) | oedxzrulwx(dlljktlwxf) = cxunqgbjry rglosrqmrg (cdtdolvgtu, 0.1917) View more | ||||||
Phase 4 | 794 | bskkzeeupv(uspgkcttxw) = twnplmofsb gsnfuhdlyx (qjjuqozjal ) View more | - | 01 Jul 2023 | |||
No β-blocker therapy | bskkzeeupv(uspgkcttxw) = hjtkyrphxz gsnfuhdlyx (qjjuqozjal ) View more |